Hematology Faculty

Division Chief

Ravindra Majeti, MD, PhD

Associate Professor

Molecular characterization of human acute myeloid leukemia stem cells and their pathogenesis using bioinformatics, genomics, microfluidics, flow cytometry, and xenotransplantation assays in mice Development of novel therapeutic monoclonal antibodies directed against human acute myeloid leukemia stem cell surface antigens Investigation of normal human hematopoiesis and hematopoietic stem cells using similar techniques

Professors

Steven E. Artandi, MD, PhD

Jerome and Daisy Low Gilbert Professor

  • Understanding the early stages of cancer development
  • Mechanisms in dyskeratosis congenita and other degenerative diseases
  • Telomerase function inside human stem cells and cancer cells

Ami Bhatt, MD, PhD

Assistant Professor

My laboratory uses molecular, micro- and computational biology techniques to dissect the role of the microbiota in hematological disorders.

We hope to target vulnerabilities in hematological disorders characterizing and modifying the human microbiota, thereby improving patient outcomes.

Caroline Bérubé, MD

Clinical Associate Professor

Medical Director Outpatient Anticoagulation Clinic

General hematology

Specific interest in clinical thrombosis and hemostasis, management of anticoagulation, hemophilia, pregnancy-related hematologic conditions, immune thrombocytopenia, and anemia.

 

 

Linda M. Boxer, MD, PhD

Stanley McCormick Memorial Professor

  • The molecular mechanisms of deregulation of the oncogenes, c-myc and bcl-2, by translocation into immunoglobulin loci
  • How deregulation of these oncogenes disrupts the normal regulatory control mechanisms in hematopoietic cells
  • Identification of critical genes and pathways in acute lymphoblastic leukemia in response to chemotherapeutic agents

Roni Brar, MD

Clinical Assistant Professor

Optimizing clinical evaluation for patients with benign and malignant hematologic conditions.

Novel clinical trials for acute myeloid leukemia, chronic lymphocytic leukemia, multiple myeloma, and other hematologic malignancies.

Implementing personalized genomic medicine with high impact results into the clinic. 

 

Steven E. Coutré, MD

Professor

Clinical evaluation of platelet antagonists, hematopoietic growth factors and novel antithrombotics Development of clinical protocols for the treatment of hematologic malignancies including acute and chronic leukemias and multiple myeloma Director, Stanford Hematology Clinic

Tamara Dunn, MD

Clinical Assistant Professor

Program Director, Hematology Fellowship Program

Lawrence Tim Goodnough, MD

Professor, Pathology & Medicine

  • Oversees and supervises rotation of Hematology/ Oncology fellows in Transfusion Service
  • Director, Transfusion Medicine Fellowship Program
  • Associate Medical Director, Stanford Blood Center
  •  

Jason R. Gotlib, MD

Professor

Phase I/II trial evaluation of novel therapies for myelodysplastic syndromes, acute myelogenous leukemia, chronic myelogenous leukemia, and chronic myeloproliferative disorders (MPDs, eg. polycythemia vera, essential thrombocythemia, primary myelofibrosis, hypereosinophilic syndromes, and systemic mastocytosis) Translational research collaborations to interrogate the molecular basis of CML and chronic MPDs
MPDs Associate Director, Stanford Myelodysplastic Syndromes Center Director, Hematology Division Tissue Bank Director, Med 8, Inpatient Hematology Service 

Peter L. Greenberg, MD

Professor, Emeritus (Active)

  • The role and mechanisms of programmed cell death (apoptosis), oncoprotein/oncogene expression, and anti-angiogenesis in hemopoietic regulation
  • Focus is given to evaluating these processes in the evolution of myelodysplastic syndromes and acute myeloid leukemia in vitro and in vivo, with emphasis on the impact of hemopoietic growth factors
  • Development of clinical protocols for treating myelodysplastic syndrome and acute myeloid leukemias
  • Director, MDS Center
  •  

David Iberri, MD

Clinical Assistant Professor

Caring for patients with multiple myeloma, Waldenström macroglobulinemia, and related plasma-cell and lymphoid disorders.

Using novel biomarkers to personalize therapy and predict treatment response

Participating in clinical trials to advance the care of patients with a variety of hematologic malignancies including MDS, AML, and CLL.

Calvin J. Kuo, MD, PhD

Maureen Lyles D'Ambrogio Professor

  • Organoid modeling of cancer
  • Intestinal stem cell biology
  • Blood-brain barrier vascular biology

Lawrence L.K. Leung, MD

Maureen Lyles D'Ambrogio Professor

  • The discovery and development of new antithrombotic reagents, targeting plasma proteases and their inhibitors, and cell adhesive proteins and their receptors on platelets and endothelial cells
  • Approaches include basic molecular and protein biochemistry to the evaluation in appropriate animal models

Michaela Liedtke, MD

Assistant Professor

Director, Stanford Adolescent and Young Adult (AYA) Cancer Program

Design of clinical trials using new therapeutic strategies and experimental therapeutics for multiple myeloma, amyloidosis and acute lymphoblastic leukemia. Translational research collaborations to investigate the pathophysiology of amyloidosis. Development of a program addressing the unique needs of adolescents and young adults with cancer.

Beth A. Martin, MD

Clinical Assistant Professor 

Clinical interests include the histiocytoses including HLH/MAS, autoimmune hematology including T-LGL, AIHA, and Castleman.  Educational interests include physical diagnosis, clinical decision-making and communication under desperate circumstances, and chemotherapy.  My research focuses on HLH.

Bruno Medeiros, MD

Affiliated Clinical Professor

My research interests focus on the experimental therapeutics of Acute Myeloid Leukemia (AML) with the ultimate goal of improving our understanding of the genomic abnormalities responsible for leukemogenesis and how these abnormalities can be exploited therapeutically. It also includes the development and incorporation of novel agents into the treatment regimens for young and older patients with AML and those with acute leukemia secondary to antecedent hematologic disorders.  

Beverly S. Mitchell, MD

George E. Becker Professor  

  • Role of nucleotides in regulating nucleolar organization, function and cell proliferation
  • Novel therapies for acute leukemia with correlative studies
  • Function of a novel DNA repair protein with ubiquitin ligase activity

Elizabeth A. Price, MD, MPH

Assistant Professor

Clinical and laboratory characterization of unexplained anemia of aging Development of clinical protocol evaluating hematologic and functional response to interventions in unexplained anemia of aging

 

Stanley L. Schrier, MD

Professor, Emeritus (Active)

Red cell biology with emphasis on the pathophysiology and cell biology of the thalassemias, the causes of anemia in malaria, and the complex consequences of anemia in the aged


Tait Shanafelt

Jeanie and Stew Ritchie Professor

Determining why people develop CLL and, its precursor condition, monoclonal B-cell lymphocytosis (MBL). 

Identifying molecular characteristics and prognostic tools that predict which CLL patients will experience a more aggressive disease course. 

  • Identification and testing of new compounds for treating CLL. 

James L. Zehnder, MD

Professor

Clinical and laboratory investigation of thrombosis and bleeding disorders Molecular diagnostic testing for inherited thrombophilia and hematololymphoid malignancy